Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipam An interim 18-month analysis of an ongoing open-label extension study demonstrated a mean reduction in tic severity scores (45.6%) with no new safety signals observed Additional analyses found that common concurrent psychiatric conditions […]
Teva Pharmaceuticals has unveiled new efficacy and safety data for ecopipam, an investigational selective D1 (dopamine) receptor antagonist intended for pediatric patients with Tourette syndrome, at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea. The data, presented at the conference from October 4–8, 2026, encompass a post hoc analysis of safety and efficacy during the initial eight weeks of treatment, long-term efficacy and safety from an ongoing open-label extension study, subgroup analyses, and preclinical receptor selectivity findings.
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
